June 17, 2016
The sodium glucose co-transporter-2 (SGLT-2) inhibitor Jardiance (empagliflozin) not only reduces cardiovascular risks in diabetes patients but also the risk of kidney disease, according to new study findings. Jardiance cut the risk for new-onset or worsening kidney disease by 39%...read more